S&P 500   3,006.72 (+0.69%)
DOW   26,827.64 (+0.21%)
QQQ   193.39 (+0.89%)
AAPL   240.51 (+1.73%)
FB   189.75 (+2.10%)
MSFT   138.39 (+0.71%)
GOOGL   1,244.23 (-0.01%)
AMZN   1,785.67 (+1.60%)
CGC   20.35 (+0.69%)
NVDA   196.11 (+2.95%)
MU   45.25 (+4.09%)
BABA   173.52 (+2.60%)
GE   8.79 (-1.90%)
TSLA   253.46 (-1.36%)
AMD   32.07 (+3.52%)
T   38.23 (-0.62%)
F   9.03 (-2.80%)
ACB   3.69 (+0.27%)
PRI   125.69 (+1.75%)
NFLX   278.05 (+1.00%)
BAC   31.02 (+2.21%)
GILD   65.22 (+0.48%)
DIS   130.26 (-0.48%)
S&P 500   3,006.72 (+0.69%)
DOW   26,827.64 (+0.21%)
QQQ   193.39 (+0.89%)
AAPL   240.51 (+1.73%)
FB   189.75 (+2.10%)
MSFT   138.39 (+0.71%)
GOOGL   1,244.23 (-0.01%)
AMZN   1,785.67 (+1.60%)
CGC   20.35 (+0.69%)
NVDA   196.11 (+2.95%)
MU   45.25 (+4.09%)
BABA   173.52 (+2.60%)
GE   8.79 (-1.90%)
TSLA   253.46 (-1.36%)
AMD   32.07 (+3.52%)
T   38.23 (-0.62%)
F   9.03 (-2.80%)
ACB   3.69 (+0.27%)
PRI   125.69 (+1.75%)
NFLX   278.05 (+1.00%)
BAC   31.02 (+2.21%)
GILD   65.22 (+0.48%)
DIS   130.26 (-0.48%)
Log in

Exagen Stock Price, News & Analysis (NYSE:XGN)

$14.53
+0.54 (+3.86 %)
(As of 10/21/2019 04:00 PM ET)
Today's Range
$13.79
Now: $14.53
$14.53
50-Day Range N/A
52-Week Range
$11.54
Now: $14.53
$19.50
Volume31,200 shs
Average Volume74,249 shs
Market Capitalization$167.01 million
P/E RatioN/A
Dividend YieldN/A
BetaN/A
Exagen Inc. operates as a commercial-stage diagnostics company, develops and markets products for the diagnosis, prognosis, and monitoring of patients affected by autoimmune rheumatic diseases (ARDs). Its lead product includes Avise SLE+CT, a proprietary diagnostic test that provides an enhanced solution for patients with a range of ARDs, such as systemic lupus erythematosus (SLE), rheumatoid arthritis (RA), Sjögren's syndrome, and scleroderma, as well as other disorders, including fibromyalgia. The company also offers Avise SLE Prognostic, a blood test that complements Avise SLE+CT; Avise MTX, a therapeutic drug monitoring test to measure levels of methotrexate polyglutamates; and Avise HCQ, a blood test for physicians to monitor blood levels of HCQ. In addition, it is developing Anti-TNF, a blood test to monitor the levels of anti-TNF bioactivity in patients with RA; Avise SLE Monitoring, a multi-analyte panel blood test for physicians to track the disease status of their SLE patients; and Avise RA, a blood test to determine bone damage or joint erosion. The company primarily serves rheumatologists in the United States. It was formerly known as Exagen Diagnostics, Inc. Exagen Inc. was incorporated in 2002 and is headquartered in Vista, California.

Industry, Sector and Symbol

Industry Diagnostics & Research
Sub-IndustryN/A
SectorMedical
CUSIPN/A
CIKN/A
Phone760-560-1501

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A

Profitability

Miscellaneous

Employees142
Market Cap$167.01 million
Next Earnings DateN/A
OptionableNot Optionable

Receive XGN News and Ratings via Email

Sign-up to receive the latest news and ratings for XGN and its competitors with MarketBeat's FREE daily newsletter.


Exagen (NYSE:XGN) Frequently Asked Questions

What is Exagen's stock symbol?

Exagen trades on the New York Stock Exchange (NYSE) under the ticker symbol "XGN."

What price target have analysts set for XGN?

3 brokerages have issued 12-month price objectives for Exagen's stock. Their predictions range from $17.00 to $18.00. On average, they expect Exagen's share price to reach $17.50 in the next twelve months. This suggests a possible upside of 20.4% from the stock's current price. View Analyst Price Targets for Exagen.

What is the consensus analysts' recommendation for Exagen?

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Exagen in the last year. There are currently 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Exagen.

Has Exagen been receiving favorable news coverage?

News articles about XGN stock have been trending somewhat positive recently, according to InfoTrie. InfoTrie identifies negative and positive press coverage by reviewing more than six thousand blog and news sources. The firm ranks coverage of companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Exagen earned a news sentiment score of 0.8 on InfoTrie's scale. They also gave headlines about the company a news buzz of 0.0 out of 10, indicating that recent press coverage is extremely unlikely to have an impact on the stock's share price in the near future. View News Stories for Exagen.

Who are some of Exagen's key competitors?

Who are Exagen's key executives?

Exagen's management team includes the folowing people:
  • Mr. Fortunato Ron Rocca, Chief Exec. Officer, Pres and Director (Age 58)
  • Ms. Wendy Swedick CPA, Chief Financial Officer (Age 54)
  • Dr. Thierry Dervieux Pharm.d., Ph.d., Chief Scientific Officer, Medical Director of New York and Medical Laboratory Director (Age 51)
  • Ms. Waneta Coester Tuttle, Founder (Age 72)
  • Mr. Cole Harris, Co-Founder

When did Exagen IPO?

(XGN) raised $50 million in an initial public offering (IPO) on Thursday, September 19th 2019. The company issued 3,300,000 shares at a price of $14.00-$16.00 per share. Cowen, Cantor and William Blair acted as the underwriters for the IPO.

When does Exagen's quiet period expire?

Exagen's quiet period expires on Tuesday, October 29th. Exagen had issued 3,600,000 shares in its initial public offering on September 19th. The total size of the offering was $50,400,000 based on an initial share price of $14.00. During Exagen's quiet period, insiders and any underwriters involved in the IPO are restricted from issuing any research reports or earnings estimates for the company because of SEC regulations. Following the expiration of the company's quiet period, the brokerages that served as underwriters will likely initiate research coverage on the company.

How do I buy shares of Exagen?

Shares of XGN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Exagen's stock price today?

One share of XGN stock can currently be purchased for approximately $14.53.

How big of a company is Exagen?

Exagen has a market capitalization of $167.01 million. Exagen employs 142 workers across the globe.View Additional Information About Exagen.

What is Exagen's official website?

The official website for Exagen is http://avisetest.com/.

How can I contact Exagen?

The company can be reached via phone at 760-560-1501.


MarketBeat Community Rating for Exagen (NYSE XGN)

Community Ranking:  3.3 out of 5 (star star star)
Outperform Votes:  6 (Vote Outperform)
Underperform Votes:  3 (Vote Underperform)
Total Votes:  9
MarketBeat's community ratings are surveys of what our community members think about Exagen and other stocks. Vote "Outperform" if you believe XGN will outperform the S&P 500 over the long term. Vote "Underperform" if you believe XGN will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 10/21/2019 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel